Sector News

Alexion announces additions to leadership team

June 2, 2017
Life sciences

Alexion Pharmaceuticals Inc. today announced key additions to its executive leadership team effective June 5, 2017.

Reporting to Chief Executive Officer, Ludwig Hantson will be: John Orloff, M.D., Executive Vice President, Head of Research & Development, Anne-Marie Law, Executive Vice President, Chief Human Resources Officer, and Indrani Lall Franchini, J.D., Executive Vice President, Chief Compliance Officer.

“I am delighted to welcome John, Anne-Marie, and Indrani to Alexion. Each of these highly talented executives brings deep industry experience and a proven track record in their respective areas of expertise,” said Ludwig Hantson, Chief Executive Officer of Alexion. “These experienced leaders join our team of exceptionally skilled and dedicated employees around the world and will be key partners as we build upon Alexion’s solid foundation to drive continued growth and deliver long-term value for all of our stakeholders.”

John Orloff, M.D., Head of Research & Development

Dr. Orloff is a global R&D business leader with 20 years of experience in the biopharmaceutical industry and deep expertise spanning various stages of clinical and non-clinical development, including developing medicines for rare diseases. As Alexion’s Head of R&D, Dr. Orloff will be focused on strengthening the Company’s clinical pipeline and research programs, enhancing R&D productivity, overseeing regulatory and medical affairs, and supporting business development. Dr. Martin Mackay, Alexion’s current Head of R&D, will work with Dr. Orloff to ensure a smooth transition of Alexion’s key pipeline programs, including the registration filings of Soliris® (eculizumab) for patients with refractory generalized myasthenia gravis (gMG) and the ALXN1210 clinical development programs.

“John’s experience in successfully developing biopharmaceuticals, including in the areas of hematology, immunology, and metabolics, as well his strong global clinical and regulatory expertise, makes him ideally suited to lead the R&D function at Alexion. John and I are aligned on the highest priority development programs, including the gMG registration filings and the ALXN1210 development programs. I’m pleased to work with John again and know him as a leader who fosters effective teams and drives innovation on a global scale to serve the needs of patients,” said Dr. Hantson.

Dr. Orloff joins Alexion from Novelion where he served as Executive Vice President, Head of Research & Development since November 2016. Previously, he was Global Head of R&D and Chief Scientific Officer at Baxalta, where he advanced the company’s pipeline and oversaw regulatory approval of 10 unique products and two devices over two years. He also held executive R&D roles with Baxter International, Merck Serono, Novartis and Merck Research Laboratories. Prior to joining the biopharmaceutical industry in 1997, Dr. Orloff was with Yale University School of Medicine for seven years. He received his A.B. from Dartmouth College and his M.D. from the University of Vermont College of Medicine, and he completed his medical training at the University of Pittsburgh Medical Center and Yale University School of Medicine.

Anne-Marie Law, Chief Human Resources Officer

Ms. Law is a human resources executive with more than 25 years of experience at global corporations with a strong track record of driving positive change and managing multi-national workforces in multiple global locations. As Alexion’s Chief Human Resources Officer, she will be focused on building the organizational capabilities to advance Alexion’s strategy.

Dr. Hantson stated, “I am very pleased to once again be partnering with Anne-Marie. She brings to Alexion a strong track record of driving positive change at global corporations and is recognized for delivering high-performance, purpose-driven organizations by building diverse, inclusive, and aligned teams.”

Ms. Law joins Alexion from Hyatt Hotels Corporation where she served as Chief Human Resources Officer responsible for building the strategy to support the company’s 100,000 employees worldwide, and designing talent systems to create world class leadership and customer connectivity capabilities. Before joining Hyatt in 2016, Ms. Law served as Executive Vice President and Head of Human Resources for Baxalta Incorporated, and held various senior human resources positions at McKesson Corporation, including the Specialty Health Division, VeriSign, and Xilinx, Inc. Ms. Law is a graduate of Leicester University with a degree in Art History in the United Kingdom and The National College of Ireland, Dublin.

Indrani Lall Franchini, J.D., Chief Compliance Officer

Ms. Franchini has extensive experience developing and building the infrastructure and company-wide standards for global compliance programs, interacting with regulatory agencies and establishing multi-functional teams to support global compliance programs. As Alexion’s Chief Compliance Officer, Ms. Franchini will be focused on enhancing Alexion’s global compliance program, ensuring it meets all legal and regulatory requirements and industry guidelines while protecting the value the Company brings to patients, the community, and external stakeholders. She will also co-lead the Company’s newly formed Global Corporate Compliance Committee.

“As we continue to grow worldwide to best serve patients, our commitment to compliance and performing with integrity has never been greater. Given that compliance and growth go hand-in-hand, Indrani, with her global biopharmaceutical experience and by partnering with colleagues across the Company, will ensure that everywhere we do business not only complies with applicable laws and regulations but also meets Alexion’s high ethical standards,” commented Dr. Hantson.

Ms. Franchini joins Alexion from Hess Corporation where she served as Chief Compliance Officer. Before joining Hess in 2012, Ms. Franchini spent nearly ten years with Pfizer, most recently as Chief Compliance Counsel for its Pharmaceutical Business, overseeing all compliance elements for the development, marketing, and promotion of this global business. Earlier in her career, Ms. Franchini served as an attorney with Milbank, Tweed, Hadley & McCloy in the firm’s New York and Tokyo offices. Ms. Franchini earned her J.D. from the University of Michigan Law School and her B.A. from Princeton University. In addition, she spent a year as a Fulbright Fellow at the Kyushu University Graduate School in Fukuoka, Japan.

Source: Alexion

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”